During the projected period of 2021–2031, the market for anticoccidial pharmaceuticals may see significant increase due to the sector's expanding development and the government bodies' increasing focus on supporting research linked to these products. Additionally, between 2021 and 2031, the global market may experience phenomenal growth due to factors including the growing prevalence of coccidiosis in companion and food-producing animals as well as the increased global awareness of animal health.
One of the most common and pervasive parasite infections in farmed animals, coccidiosis causes weight loss, mild to severe diarrhoea, faeces that are bloody or mucusy, dehydration, and reduced fertility. Eimeria, a kind of single-celled parasite (protozoa) that has a straightforward life cycle in the gut, is the cause of coccidiosis. Any medication used to stop the spread of coccidiosis in birds or other animals—both those that produce food and those that do not—is referred to as an anticoccidial.
The single cell parasite that causes the common illness, coccidiosis, can only be seen through the microscope. It may affect any type of cattle as well as wild animals, and it is frequently prevalent when animals or birds are huddled together in large groups. The illness causes death in the flock and reduces the ability of hens to lay eggs.
The anticoccidial drugs market may be divided into coccidiostatic and coccidiocidal types of medications based on actions. The anticoccidial drug market can be further dividedsegmented into ionophores and synthetic anticoccidials on the basis of medicinal entity. The section of ionophores may further be broken down into monovalent, monovalent glycoside, and divalent types. Ionophores are the byproducts of fungus species' fermentation. They are widely employed as anticoccidial substances.
The report on the market for anticoccidial drugs considers critical competitive information, including corporate strategy, product portfolio, significant developments, SWOT analysis, and research and development priorities of all Anticoccidial Drugs businesses. The participants involved in the market's supply chain and value chain, as well as their contributions, will be taken into account in the global anticoccidial drugs market analysis.
The anticoccidial drugs market is competitive. While embracing expansion tactics including mergers, acquisitions, and alliances with other market participants, major firms are largely concentrating on ongoing product development.
Boehringer Ingelheim International GmbH, Merck and Co. Inc., Qilu Animal Health Products Co., Ltd., Huvepharma EOOD, and VH Group are major companies within the anticoccidial drugs market.
The introduction of the first polyether monensin, and ionophore anticoccidial, in 1972, represented a significant advance in the treatment of feed to avoid coccidiosis. Ionophores are the popular name for this class of anticoccidial drug, which is derived from its basic chemical makeup. Streptomyces and other fungal species produce ionophores as byproducts of fermentation.
Recent trends in the anticoccidial drugs market include rising prophylactic anticoccidial medication use and rising demand for meat proteins. Additionally, looser laws and increasing government expenditure on pets are contributing to the rise of the anticoccidial drugs market.
The largest regional market for anticoccidial drugs market is North America. The availability of several anticoccidial medications, including chemical and polyether ionophores, as well as the preventive use of anticoccidials in animal feed, might be credited for this. Additionally, factors like increased consumer awareness of coccidiosis prevention, a secure supply of animal feed, and significant R&D expenditure, primarily for the development of novel products, are predicted to fuel the growth of the North America anticoccidial drugs market during the anticipated period of 2021-2031.
Asia Pacific is estimated to emerge as a rapid growth-generating region for the anticoccidial drugs market. The rising awareness about the disease among a considerable chunk of the populace in the region may serve as a prime growth-boosting factor for the anticoccidial drugs market in Asia Pacific.